Stock Market News
Physiomics shares jump as new 'virtual tumour' contract signed
Shares are on the rise in cancer technology company Physiomics after it announced a contract with a major global top 10 pharmaceutical client.
The company's shares rose 10% to 7.98p by mid-afternoon on Friday in response to news of the new contract.
The project, which will be completed in 2018, involves use of Physiomics' virtual tumour technology, which simulates tumour reactions to different treatments, in a pre-clinical setting and is understood to be worth approximately £70,000.
Dr Jim Millen, chief executive of Physiomics, said: "We believe that the signing of agreements with three major pharmaceutical clients within the space of three months is a real sign of the confidence in our technology that is starting to build within the industry."
The company won a contract with an unnamed major pharma company in January and entered into a master services agreement with leading science and technology company Merck in November.
"Our aim now will be to develop longer-term relationships with these major companies and to secure further pre-clinical and clinical projects," said Mullen.
The company's shares rose 10% to 7.98p by mid-afternoon on Friday in response to news of the new contract.
The project, which will be completed in 2018, involves use of Physiomics' virtual tumour technology, which simulates tumour reactions to different treatments, in a pre-clinical setting and is understood to be worth approximately £70,000.
Dr Jim Millen, chief executive of Physiomics, said: "We believe that the signing of agreements with three major pharmaceutical clients within the space of three months is a real sign of the confidence in our technology that is starting to build within the industry."
The company won a contract with an unnamed major pharma company in January and entered into a master services agreement with leading science and technology company Merck in November.
"Our aim now will be to develop longer-term relationships with these major companies and to secure further pre-clinical and clinical projects," said Mullen.
Related share prices |
---|
Physiomics (PYC) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price